CHIMERIC THERAPEUTICS LIMITED — Investor Presentation 2021

Mar 17, 2021

==> picture [144 x 194] intentionally omitted <==

© Copyright Chimeric Therapeutics | Private and Confidential | March 2021

Disclaimer

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

2

==> picture [307 x 540] intentionally omitted <==

----- Start of picture text -----

Bringing the
Promise of Cell
Therapy to Life
----- End of picture text -----

==> picture [65 x 59] intentionally omitted <==

==> picture [63 x 59] intentionally omitted <==

==> picture [65 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

At Chimeric we are focused on bringing the promise of cell therapy to life for patients with cancer.

Chimeric is a clinical stage cell therapy company which was founded on promising Chlorotoxin (CLTX) CAR T technology from City of Hope.

Chimeric has completed two capital raisings totalling A$39.3 million and was listed on the Australian Securities Exchange on 18[th] January 2021.

Chimeric is currently further developing our oncology pipeline with novel cell therapy technologies that will provide benefit to cancer patients globally

Chimeric Therapeutics believes that we are uniquely positioned for success as we combine our cell therapy development and commercialization expertise with the worlds most innovative scientists and clinicians

Cell Therapy Development

What is Cell Therapy? Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease. The global market for cell therapies is estimated to reach between USD $8-9 billion by 2026 Cell therapy is the most active sector in biotech today, with financing reaching $19.9B in 2020, doubling from 2019

==> picture [906 x 34] intentionally omitted <==

----- Start of picture text -----

Acquisitions IPO’s Follow On Offerings Partnerships
----- End of picture text -----

Aug 2017: US$11.9b	February 2021 US$587M	June 2020 US$550M	Jan 2021 US$90M upfront
			to $1.8B
	January 2021	June 2020
	US$209M	US$604M
Jan 2018: US$9b	June 2020 US$487M	June 2020 US$517M	Apr 2020 US$100M upfront to $3B

4

The Promise of Cell Therapy: Curative Potential in Cancer

In oncology, cell therapy launched with the promise to be a therapeutic revolution as it demonstrated survival not previously seen with chemotherapies or immunotherapies.

Today, data from CAR T trials in R/ R DLBCL has shown that ~50% of patients who would have been expected to only survive 6 months are alive and with no evidence of disease 4 years after being treated with a CAR T therapy.

This long-term survival of patients with deadly cancers represents the promise of cell therapy – curative potential in cancer.

Time

==> picture [85 x 125] intentionally omitted <==

----- Start of picture text -----

CAR T Therapy
Immunotherapy
Chemotherapy
----- End of picture text -----

5

What is CAR T Cell Therapy?

C himeric A ntigen R eceptor T (CAR T) Cell Therapy is a type of cell therapy that modifies a patient’s own immune cells (T-cells) to use directly against their cancer.

==> picture [712 x 333] intentionally omitted <==

----- Start of picture text -----

INSIDE THE BODY
Cancer Antigen Target
Cancer
CAR T
Cell
Cell
C himeric A ntigen
R eceptor
A patient’s cells are engineered to Once inside the body, the CAR T cells
express a receptor on their surface that seek out the antigen targets on cancerous
recognizes structures (antigens) on the cells. The Chimeric Antigen Receptor
surface of malignant cells. then binds to the cancerous cells.
----- End of picture text -----

==> picture [74 x 46] intentionally omitted <==

Once the CAR T cells binds to the cancerous cells it sends a signal to attack the tumour cell. Each CAR T cell can produce more than 10,000 new cells to target and kill the cancer

A patient’s cells are engineered to express a receptor on their surface that recognizes structures (antigens) on the surface of malignant cells.

Source: Penn Medicine: Abramson Cancer Centre 6

Chlorotoxin (CLTX) CAR T First in Class

In 2020, Chimeric Therapeutics licensed the exclusive global rights to the Chlorotoxin (CLTX) CAR T cell therapy developed at the City of Hope Cancer Centre.

CLTX CAR T has a long life, composition of matter intellectual property profile expiring 2036.

CLTX CAR T is a first-in-class peptide-toxin CAR T, utilizing Chlorotoxin, a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting domain.

Chlorotoxin has an established safety profile in humans as it has been used as an imaging agent.

The range of tumours bound by CLTX is promising and suggests significant therapeutic potential in many solid tumours.

==> picture [394 x 505] intentionally omitted <==

----- Start of picture text -----

T Cell
----- End of picture text -----

7

Unmet Medical Need in Glioblastoma

More than 300,000 patients globally are diagnosed each year with brain and nervous system cancer, and GBM is the most common and most lethal of these cancers

~8 months median overall survival for patients diagnosed with GBM

==> picture [233 x 202] intentionally omitted <==

~38% of patients with GBM survive one year survival

~ 5% of patients with GBM survive five years

• 3 FDA approved therapies and no standard of care in recurrent GBM

2009 last FDA approved therapy, Bevacuzimab demonstrated no overall survival benefit

8

Chlorotoxin (CLTX) CAR T: Potential Best in Class

Due to the unique preclinical properties that CLTX CAR T has shown, it has the potential to address the high unmet medical need for effective therapy against recurrent glioblastoma (WHO grade III-IV)

Broad Recognition and Binding of GBM Cells

Preclinical Safety

Activity

CLTX has been shown to more specifically and broadly target GBM cells than other immunotherapies

==> picture [151 x 202] intentionally omitted <==

CLTX CAR T has demonstrated excellent safety with no off tumour recognition of normal healthy cells in preclinical models

==> picture [290 x 88] intentionally omitted <==

CLTX CAR T has demonstrated potent anti-tumour activity in vivo with significantly improved survival in mice

==> picture [211 x 193] intentionally omitted <==

9

Phase 1 Clinical Study in Recurrent Glioblastoma Patient dosing commenced late September 2020 at City of Hope

Primary Objective: To assess the safety of CLTX CAR T cells for patients with MMP2 recurrent GBM and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan

• Approximately 18 -36 patients with recurrent or progressive GBM

• Dose escalation of 44 X 10[6] to 440 X 10[6] CLTX CAR T cells

• Two administration methods being examined; single route intratumoral delivery and dual route intratumoral and intraventricular delivery

==> picture [422 x 263] intentionally omitted <==

----- Start of picture text -----

ICT and ICV Administration
Total dose: 440 X 10 [6]
Intratumoral Delivery ICT and ICV Administration
Total dose: 220 X 10 [6]
ICT and ICV Administration
Total dose: 88 X 10 [6]
Intratumoral Delivery ICT Administration
Total dose: 44 X 10 [6]
FDA mandated staggered dosing
----- End of picture text -----

ICT: Intracranial intratumoral or intracavitary ICV: Intracranial intraventricular

10

PHASE 1 CLTX CAR T Update (as of March 18, 2021)

Successful Completion of Planned Dosing in First Patient Cohort

Chimeric Therapeutics, a clinical stage cell therapy company, is pleased to announce the successful completion of the planned dosing of the first patient cohort (n=4) in the phase 1 dose escalation study, evaluating the safety and maximum tolerated dose of Chimeric’s Chlorotoxin CAR T (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM).

The dosing of this patient marks the completion of planned dosing in the first and lowest dose level. Patients in this dose cohort were dosed via single site administration (intracranial intratumoral or intracavitary (ICT) administration) at a dose of 44 X 10[6] CLTX CAR T cells.

As the final patient of this first dose cohort successfully completes the DLT period, the study will begin to recruit patients for the next dose level which will introduce dual administration (ICT administration and intracranial intraventricular (ICV) administration) at a dose of 88 X 10[6] CAR T cells.

==> picture [380 x 270] intentionally omitted <==

----- Start of picture text -----

ICT and ICV Administration
Total dose: 440 X 10 [6]
Intratumoral Delivery ICT and ICV Administration
Total dose: 220 X 10 [6]
ICT and ICV Administration
Total dose: 88 X 10 [6]
Intratumoral Delivery ICT Administration
Total dose: 44 X 10 [6]
FDA mandated staggered dosing
----- End of picture text -----

ICT: Intracranial intratumoral or intracavitary ICV: Intracranial intraventricular

11

CLTX CAR T in Recurrent Glioblastoma Preparing for Rapid Advancement to a Registration Trial

A Phase 2 Single Arm Pivotal Trial to Evaluate CLTX Chimeric Antigen Receptor (CAR) T cells in Patients with Recurrent / Progressive GBM

Phase 1 Recurrent GBM

PIVOTAL PHASE 2 Recurrent GBM

Target Indication : Relapsed/ Refractory Glioblastoma Target Sample Size: n= ~75

Participating Sites : Multi centre global trial sites

With the lack of a standard of care and high unmet need for patients with recurrent/ progressive GBM, a single arm pivotal phase 2 trial is anticipated, based on precedents in DLBCL, MCL and MM to meet FDA requirements for approval

12

CLTX CAR T Expanding into Additional Tumour Types

Based on evidence of CLTX binding in other solid tumours we are currently exploring initiation of a phase 1 basket trial in melanoma, colorectal cancer, prostate cancer , small cell lung cancer and sarcomas

POTENTIAL INDICATIONS FOR CLTX-CAR T CLINICAL TRIALS INCLUDE:

==> picture [662 x 215] intentionally omitted <==

----- Start of picture text -----

Glioblastoma Colorectal
Melanoma Neuroectodermal Small Cell Lung
and other tumors that
have been shown to
bind CLTX
Prostate
Ewing’s Sarcoma
----- End of picture text -----

(Lyons et al. Glia 2002)

13

Building the Chimeric Therapeutics Pipeline

Novel Allogeneic Alternative Chimeric is focused CAR Cell Cell Designs Sources Types on enhancing our pipeline with innovative cell therapies for oncology

14

Uniquely Positioned for Success in Cell Therapy Development

We recognize that there are novel challenges in the development and commercialization of cell therapies that our experience makes us uniquely positioned to address

==> picture [92 x 92] intentionally omitted <==

Jennifer Chow Chief Operating Officer

==> picture [91 x 91] intentionally omitted <==

Dr Syed Rizvi Chief Medical Officer

==> picture [88 x 87] intentionally omitted <==

Dr Eliot Bourk Head, Business and Corporate Development

• § Kite Pharma, Head of Global Marketing, Commercial Operations and Analytics

• § Celgene, Global Cell Therapy Commercial Lead

• § 20+ years of commercial biotech experience in oncology

§ Legend Biotech, Head of Clinical Development and Medical Affairs

• § Celgene, Global Cell Therapy Medical Affairs Lead

• § 20+ years of medical biotech experience in oncology

• § Kite Pharma, Head of Early Commercial Development

• § Celgene, Global Cell Therapy Commercial Strategy and Next Generation Platforms

• § PhD in cancer immunology and 10+ years in oncology

==> picture [70 x 33] intentionally omitted <==

==> picture [36 x 33] intentionally omitted <==

==> picture [42 x 22] intentionally omitted <==

==> picture [76 x 36] intentionally omitted <==

==> picture [37 x 32] intentionally omitted <==

==> picture [77 x 13] intentionally omitted <==

==> picture [71 x 33] intentionally omitted <==

==> picture [36 x 32] intentionally omitted <==

==> picture [64 x 15] intentionally omitted <==

15

Chimeric Therapeutics Board of Directors

==> picture [92 x 92] intentionally omitted <==

==> picture [75 x 21] intentionally omitted <==

==> picture [71 x 33] intentionally omitted <==

==> picture [81 x 26] intentionally omitted <==

Paul Hopper Executive Chairman

Paul is the Founder of Chimeric and has over 25 years experience in the biotech, healthcare and life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO, of more than fourteen companies in the US, Australia and Asia. Previous Boards include Viralytics (sold to Merck in 2018 for $500m), pSivida, Somnomed, and Fibrocell Science. His experience covers extensive fund raising in Australia, Asia, US and Europe, and he has deep experience in corporate governance, risk and strategy.

==> picture [91 x 92] intentionally omitted <==

==> picture [46 x 28] intentionally omitted <==

==> picture [58 x 18] intentionally omitted <==

==> picture [62 x 23] intentionally omitted <==

==> picture [52 x 25] intentionally omitted <==

Dr Lesley Russell Non-Executive Director

Ms. Russell has 25+ years of senior international operational and leadership experience having worked at Amgen, Eli Lilly, Teva, and Cephalon. Extensive knowledge and experience with new drug development along with CAR T therapies. Non-Executive Director of Enanta Pharmaceuticals and Imugene Ltd.

==> picture [91 x 92] intentionally omitted <==

==> picture [64 x 30] intentionally omitted <==

==> picture [58 x 22] intentionally omitted <==

Ms Leslie Chong Non-Executive Director

Ms Chong is currently Chief Executive Officer and Managing Director of Imugene and Non-Executive Director of Cure Brain Cancer Foundation (CBCF).

Ms. Chong has 21+ years of oncology experience with comprehensive clinical development experience in global Phase I-III studies from start up to registration. Prior to Umgene, Ms. Chong was the Senior Clinical Program Lead at Genentech

==> picture [91 x 98] intentionally omitted <==

==> picture [55 x 24] intentionally omitted <==

==> picture [58 x 22] intentionally omitted <==

Ms Cindy Elkins Non-Executive Director

Ms. Elkins was Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers. Her role evolved into Head of Global CAR T Patient Experience with the acquisition of Juno by Celgene. Prior to Juno, Ms. Elkins was Vice President of Pharma Informatics at Genentech/Roche, where she was instrumental in ensuring all technology systems/processes were ready as soon as the FDA approved new medicines such as Zelboraf®, Gazyva®, Cotellic® and Tecentriq®.

16

The Year Ahead 2021

==> picture [349 x 90] intentionally omitted <==

----- Start of picture text -----

Define manufacturing
CLTX CAR T in GBM
strategy for Phase 2 trial
Q1 Q2
----- End of picture text -----

==> picture [116 x 28] intentionally omitted <==

----- Start of picture text -----

Phase 1 clinical trial
patient update
----- End of picture text -----

==> picture [39 x 48] intentionally omitted <==

----- Start of picture text -----

Q3
----- End of picture text -----

Select contract research organization for Phase 2 trial

==> picture [39 x 48] intentionally omitted <==

----- Start of picture text -----

Q4
----- End of picture text -----

Develop phase 1 protocol for investigation of CLTX CAR T into other tumor types

Explore collaborations for CLTX with complementary technologies

Enhance the Chimeric pipeline with novel cell therapies for oncology

Selected activities in 2021, not a comprehensive representation

17

==> picture [137 x 175] intentionally omitted <==

Bringing the Promise of Cell Therapy to Life

Inspired focus on developing cellular therapies to change the course of history for cancer patients Promising CLTX CAR T in phase 1 clinical trials in GBM with a fast to market registration path and potential in other diseases

Expanding pipeline with novel cell therapies and a unique approach to scientific partnership Cell therapy expertise to overcome the challenges of cell therapy development and commercialization and bring innovation to life

Getting to Know Cell Therapy

Allogeneic : The transfer of tissue or cells from one person to a distinct member of the same species.

Antibodies : Proteins that help fight infections and toxins and are found in the blood. They are made by B lymphocytes. Each antibody binds to a specific part of a protein or antigen.

Antigens: A part of a protein or other molecule that causes an immune response. Antigens are found in toxins, bacteria, molds, and viruses. They are also found on infected cells, proteins found on foreign blood cells (such as AB blood groups in transfusions), and, in some instances, proteins on the cells of transplanted organs. Antigens can induce the production of antibodies (immunoglobulins) and/or induce T lymphocytes to kill cells or suppress the immune response.

Autologous : Removal of tissue or cells from one person and then returning the cells back to the same person.

Cell Therapy: Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells).

CAR T Cell Therapy : C himeric A ntigen R eceptor T- Cell Therapy is a way of modifying the patient’s own immune cells (T-cells) to express a receptor on their surface that recognizes structures (antigens) on the surface of malignant cells. Once the receptor binds to a tumor antigen, the T-cell is stimulated to attack the malignant cells.

GBM : Glioblastoma or GBM is an aggressive type of cancer that can occur in the brain or spinal cord.

Preclinical Studies: Refers to the testing of experimental drugs or therapies in the test tube or in animals. The testing occurs before trials in humans may be carried out.

19

==> picture [144 x 194] intentionally omitted <==

Contact Jennifer Chow Chief Operating Officer jchow@chimerictherapeutics.com 908-723-8387